122 related articles for article (PubMed ID: 11099899)
1. Free radical formation and oxyhemoglobin oxidation in beta-thalassemic red blood cells in the presence of prooxidants: effects of the free radical scavenger rutin and oral chelator L1.
Afanas'ev IB; Afanas'ev II; Deeva IB; Korkina LG
Transfus Sci; 2000 Dec; 23(3):237-8. PubMed ID: 11099899
[No Abstract] [Full Text] [Related]
2. L1 effects on reactive oxygen (ROS) and nitrogen species (RNS) release, hemoglobin oxidation, low molecular weight antioxidants, and antioxidant enzyme activities in red and white blood cells of thalassemic patients.
Korkina L; De Luca C; Deeva I; Perrotta S; Nobili B; Passi S; Puddu P
Transfus Sci; 2000 Dec; 23(3):253-4. PubMed ID: 11099907
[No Abstract] [Full Text] [Related]
3. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.
Shalev O; Repka T; Goldfarb A; Grinberg L; Abrahamov A; Olivieri NF; Rachmilewitz EA; Hebbel RP
Blood; 1995 Sep; 86(5):2008-13. PubMed ID: 7655028
[TBL] [Abstract][Full Text] [Related]
4. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
Jirasomprasert T; Morales NP; Limenta LM; Sirijaroonwong S; Yamanont P; Wilairat P; Fucharoen S; Chantharaksri U
Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
[TBL] [Abstract][Full Text] [Related]
5. Prospects for introducing deferiprone as potent pharmaceutical antioxidant.
Kontoghiorghes GJ
Front Biosci (Elite Ed); 2009 Jun; 1(1):161-78. PubMed ID: 19482634
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients.
Morales NP; Rodrat S; Piromkraipak P; Yamanont P; Paiboonsukwong K; Fucharoen S
Biomed Pharmacother; 2022 Jan; 145():112381. PubMed ID: 34736078
[TBL] [Abstract][Full Text] [Related]
7. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
[No Abstract] [Full Text] [Related]
8. Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.
Chakraborty D; Bhattacharyya M
Mol Cell Biochem; 2000 Jan; 204(1-2):17-20. PubMed ID: 10718620
[TBL] [Abstract][Full Text] [Related]
9. Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload.
Srichairatanakool S; Ounjaijean S; Thephinlap C; Khansuwan U; Phisalpong C; Fucharoen S
Hemoglobin; 2006; 30(2):311-27. PubMed ID: 16798656
[TBL] [Abstract][Full Text] [Related]
10. Iron complexes of deferiprone and dietary plant catechols as cytoprotective superoxide radical scavengers(1).
Moridani MY; O'Brien PJ
Biochem Pharmacol; 2001 Dec; 62(12):1579-85. PubMed ID: 11755110
[TBL] [Abstract][Full Text] [Related]
11. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.
Timoshnikov VA; Kobzeva TV; Polyakov NE; Kontoghiorghes GJ
Free Radic Biol Med; 2015 Jan; 78():118-22. PubMed ID: 25451643
[TBL] [Abstract][Full Text] [Related]
13. Arthropathy in thalassaemia patients receiving deferiprone.
Berkovitch M; Laxer RM; Inman R; Koren G; Pritzker KP; Fritzler MJ; Olivieri NF
Lancet; 1994 Jun; 343(8911):1471-2. PubMed ID: 7911181
[TBL] [Abstract][Full Text] [Related]
14. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
J Pediatr Endocrinol Metab; 2000 Jun; 13(6):677-80. PubMed ID: 10905396
[TBL] [Abstract][Full Text] [Related]
15. Effects of deferiprone on immune status and cytokine pattern in thalassaemia major.
Del Vecchio GC; Schettini F; Piacente L; De Santis A; Giordano P; De Mattia D
Acta Haematol; 2002; 108(3):144-9. PubMed ID: 12373086
[TBL] [Abstract][Full Text] [Related]
16. Salivary measurement of deferiprone concentrations and correlation with serum levels.
Pope E; Berkovitch M; Klein J; Fassos F; Koren G
Ther Drug Monit; 1997 Feb; 19(1):95-7. PubMed ID: 9029756
[TBL] [Abstract][Full Text] [Related]
17. Effect of transfusion on lipid peroxidation products in the plasma of thalassemic patients.
Sher GD; Bartfay WJ; Liu PP; Lehotay DC
Transfusion; 1999 Mar; 39(3):333-4. PubMed ID: 10204599
[No Abstract] [Full Text] [Related]
18. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
Barman Balfour JA; Foster RH
Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
[TBL] [Abstract][Full Text] [Related]
19. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
20. Antiradical and chelating effects in flavonoid protection against silica-induced cell injury.
Kostyuk VA; Potapovich AI
Arch Biochem Biophys; 1998 Jul; 355(1):43-8. PubMed ID: 9647665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
